International announces new research facility
PROTON Partners International announced
it is to undertake a major genomics programme following the opening of its
cancer treatment Centres in the UK. The company signed a 10 year lease to
establish a research Centre at the Life Sciences Accelerator building in
Liverpool which is due to open in 2017. The building is the 1st part of a
'health campus' that is set to surround the ?335m new Royal Liverpool Hospital.
The lease is with The Royal and Liverpool Broadgreen University Hospitals NHS
The Proton Partners genomics programme will collate, analyse and distribute data
from its treatment Centres which will support its broader research work with the
University of Liverpool's Physics Department.
The company's 1st proton beam therapy Centre, and the 1st to be built in
the UK; is under construction at Newport, Wales, and will be offering proton
beam therapy treatment from 2017. A 2nd Centre in Northumberland is also
under construction and planning application has been submitted to build a third
at Reading, Berkshire. Other Centres are also under consideration.
Dr Steven Powell, director of Liverpool Life Sciences Accelerator, said:-
"The Liverpool Life Sciences Accelerator brings the latest medical innovators to
the City of Liverpool so that our patient population can benefit from their
expertise. Proton Partners International is one of our 1st tenants and is set to
make a big impact in healthcare."
Mike Moran, chief executive of Proton Partners International, said:- "We
are delighted to be making this commitment to establish our Research and Data
Centre in what is going to be a flagship healthcare research building in the UK.
From the outset, we have said that in addition to providing the most advanced
proton beam therapy treatment available to both private and NHS patients we will
support that with extensive research programmes that will add to the developing
knowledge of proton treatment. This data will not only be useful for our
purposes but we hope to share it with our clinical partners and stakeholders."
Professor Karol Sikora, medical director of Proton Partners International,
said:- "The future of cancer treatment is about personalisation.
Understanding the differences between cancer and normal cells in an individual
increasingly requires detailed genomic knowledge. Together with advanced imaging
technology this will help to decide the best possible way of delivering
radiotherapy as well as chemotherapy.
Optimising cancer treatment will require the in depth study of large data sets
from a huge number of patients. We are delighted to help Liverpool get to the
forefront of the global endeavour in this fascinating area of research."